Table 2.
Previous immunosuppressive therapies, RTX administration and its adverse events
| Author | Year | Previous immunosuppressive therapies | RTX administration | Adverse events |
|---|---|---|---|---|
| Cortazar | 2019 | Pred, CsA, FK, MMF, Abat, Cyc, Aza | 9 g (7.5–11 g), 1 g IV dose, 4-month interval | 1 cellulitis, 1 Clostridium difficile colitis |
| Fenoglio | 2018 | NA | 4 × 375 mg/m2, 1-week interval | None |
| Iwabuchi | 2018 | Pred, CsA, FK, MMF, Cyc, MZ | 4 × 375 mg/m2, 6-month interval | 19.7% infusion reactions, 1 neutropenia |
| Katsuno | 2018 | Pred, CsA, FK, MMF, Cyc, MZ | 1 × 500 mg (3), 2 × 500 mg (3), 3 × 500 mg (1), 3100 mg (1, seven times) | 1 hypotension |
| DaSilva | 2017 | Pred, CsA, FK, MMF, Cyc | 1 × 1 g (10), 2 × 1 g (9), 3 × 1 g (5), 4 × 1 g (4), 1788 ± 704 mg | 1 chills, 1 skin rash |
| King | 2017 | Pred, CsA, FK, MMF, Cyc, Lev, rapamycin, sirolimus | 2 × 1 g, 2 weeks apart | None |
| Ren | 2017 | Pred, CsA, FK, MMF, Cyc, Aza | 4 × 375 mg/m2, 1-week interval | None |
| Roccatello | 2017 | NA | 8 × 375 mg/m2, 1-week interval | NA |
| Brown | 2017 | Pred, CsA, FK, MMF, Cyc | 2 × 1g 2–3 weeks interval | Upper respiratory infection (3), neutropenia, disorientation and confusion 2 weeks after infusion |
| Papakrivopoulou | 2016 | Pred, CsA, FK, MMF, Cyc, Aza, Lev | 2 × 1 g, 6 months apart, 1–3 g | 1 lower respiratory tract infection, 1 gastroenteritis, 7 Type I hypersensitivity reactions |
| Dekkers | 2015 | Pred, CsA, FK, MMF, Cyc | 2 × 375 mg/m2 | 1 allergic reaction |
| Miyabe | 2015 | Pred, CsA, FK, MMF, Cyc, MZ | 4 × 375 mg/m2 (25), 6-month interval | 1 neutropenia, 1 agranulocytosis mild infusion reactions occurred in 31 patients (57 %): itching, exanthema and pharyngalgia |
| Bruchfeld | 2014 | Pred, CsA, FK, MMF, Cyc, MZ | 2 × 500 mg (8), 2 × 1 g (3), 3 × 375 mg/m2 (1), 4 × 375 mg/m2 (4) | 1 hypotension, 1 itchy and red eye |
| Guitard | 2014 | Pred, CsA, FK, MMF, Cyc, Aza | 1 × 1 g (1), 2 × 1 g (21), 2 × 1 g (5), 3 × 375 mg/m2 (2), 4 × 375 mg/m2 (12) | 2 dyspnea, 1 thoracic pain, 2 urinary tract infections |
| Iwabuchi | 2014 | Pred, CsA, FK, MMF, Cyc, MZ | 4 × 375 mg/m2, 6-month interval | 9 infusions reactions (36%) such as cough and hiccups; 1 exanthema, 1 leukopenia |
| Ruggenenti | 2014 | Pred, CsA, Cyc, Aza, MMF | 1 × 375 mg/m2 or 2 × 375 mg/m2 | 5 infections, 1 seizure, 1 biliary colic, 1 melanoma |
| Takei | 2013 | Pred, MMF, CsA, MZ | 2 × 375 mg/m2 (25), 6-month interval | 5 infusion reactions such as cough and hiccough, 1 leukopenia, 1 exanthema |
| Munyentwali | 2013 | Pred, CsA, FK, MMF, Cyc, Aza, Lev, chlorambucil | 1 × 375 mg/m2 (1), 2 × 375 mg/m2 (7), 3 × 375 mg/m2 (4), 4 × 375 mg/m2 (3) | None |
| Kronbichler | 2013 | Pred, CsA, MMF | 4 × 375 mg/m2 | NA |
| Kong | 2012 | Pred, CsA, FK, MMF, Cyc, Aza, chlorambucil | 1 × 500 mg, 1 × 600 mg, 4 × 600 mg, 1 × 700 mg, 2 × 700 mg | 1 bronchopneumonia, infusion reactions (skin rash, throat irritation, chest tightness, difficulty in breathing, hypotension, bradycardia and body ache) |
| Hoxha | 2011 | Pred, CsA, FK, MMF, Cyc, Aza, Lev | 1 × 375 mg/m2 | None |
Abat, abatacept; Aza, azathioprine; CsA cyclosporine; Cyc, cyclophosphamide; FK, tacrolimus; Pred, prednisone; Lev, levamisole; MZ, mizoribine; NA, not available; IV, intravenous.